Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 immunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of ≥500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946)

S. Kundu-Raychaudhuri, A. Sevin, P. Kilgo, M. Nokta, Richard B Pollard, T. C. Merigan

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

AIDS Clinical Trials Group (ACTG) 246/946 was a double-blinded, randomized, controlled trial of HIV-1 MN rgp160 ImmunoAG vaccine in HIV-infected patients with CD4+ T cell counts ≥500 and 200-400/mm3. The main objectives were to study the safety and immunogenicity of this vaccine and to study the persistence of the immune responses after vaccination over a longer period of time. Fifteen patients with CD4+ T cell counts of ≥500/mm3 were enrolled in the ACTG 246 study. ACTG 246 patients received a monthly injection of vaccine or control for 6 months and then injections every 2 months. After completion of this study, seven new patients with CD4+ T cell counts of 200-400/mm3 entered into the ACTG 946 study. These study patients received highly active antiretroviral therapy (HAART) (ritonavir, didanosine, and stavudine) for 9 weeks to stabilize their viral load and then each patient received a monthly injection of vaccine or control substance for 6 months with HAART. The study of these two relatively small populations showed that the vaccine was safe without any adverse effect both in the patients with CD4+ T cell counts of ≥500 and 200-400/mm3. The vaccine was also immunogenic in patients with CD4+ T cell counts of ≥500/mm3 as measured by gp160-specific lymphocyte proliferative responses, and it persisted after they had received more than six vaccine injections, for a longer period of time.

Original languageEnglish (US)
Pages (from-to)1371-1378
Number of pages8
JournalAIDS Research and Human Retroviruses
Volume17
Issue number15
DOIs
StatePublished - 2001
Externally publishedYes

ASJC Scopus subject areas

  • Immunology
  • Virology

Fingerprint Dive into the research topics of 'Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 immunoAG vaccine in HIV-infected individuals with CD4<sup>+</sup> T cell counts of ≥500 and 200-400/mm<sup>3</sup> (AIDS Clinical Trials Group Study 246/946)'. Together they form a unique fingerprint.

  • Cite this